<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167490</url>
  </required_header>
  <id_info>
    <org_study_id>IEO S637/311</org_study_id>
    <nct_id>NCT02167490</nct_id>
  </id_info>
  <brief_title>Sentinel Node Vs Observation After Axillary Ultra-souND</brief_title>
  <acronym>SOUND</acronym>
  <official_title>A Randomized Trial Comparing Sentinel Lymph Node Biopsy Vs no Axillary Surgical Staging in Patients With Small Breast Cancer and a Negative Preoperative Axillary Assessment (IEO S637/311)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this trial are that:

        -  avoiding axillary surgery does not worsen the outcome of patients with small breast
           cancer the absence of the pathological information on the risk of recurrence given by
           nodal status is not worsening outcome of these patients

        -  pre-operative imaging of the axilla can identify patients with clinically relevant nodal
           burden.

      The aims of this prospective randomized study are:

        -  to verify whether, in presence of a negative preoperative axillary assessment, SLN can
           be spared

        -  to verify whether, in presence of a negative preoperative axillary assessment, the
           decision on adjuvant medical treatment can be taken according only to the biology of the
           tumour without the prognostic information achieved by SLNB on the nodal status

        -  to verify whether, in presence of a negative preoperative axillary assessment, the
           patients' quality of life can be improved by a less invasive surgical procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sentinel lymph node biopsy (SLNB) is the standard approach for axillary staging in patients
      with breast cancer worldwide. The evident trend of breast cancer treatment is going towards
      minimizing axillary surgery, even in presence of involvement of the sentinel lymph node
      (SLN). In fact, it is well known that removal of lymph nodes is performed with staging
      purposes and to improve regional control but not with curative intent. Recent data from a
      prospective randomized trial which compared axillary dissection vs. no further axillary
      surgery in presence of positive SLN did not show any difference in term of overall and
      disease-free survival. Moreover, to date the impact of the prognostic information of axillary
      lymph node status in the decision-making process is less important than in the past as the
      adjuvant treatment is more and more tailored on the biological features of the disease rather
      than on the risk of recurrence.

      This is a prospective randomized controlled trial in which patients with small breast cancer
      (T&lt;2 cm), with a negative preoperative assessment of the axilla (ultra-sound with FNAC in
      presence of doubtful findings) will be randomized into two treatment arms:

        -  SLNB Â± axillary dissection

        -  No axillary surgical staging In the arm 1, no axillary dissection will be performed in
           case of either negative SLN or in presence of isolated tumour cells or micrometastases.
           SLNB will be completed by axillary dissection in presence of macrometastases diagnosed
           in the SLN.

      The aims of this prospective randomized study are:

      to verify whether, in presence of a negative preoperative axillary assessment, SLN can be
      spared to verify whether, in presence of a negative preoperative axillary assessment, the
      decision on adjuvant medical treatment can be taken according only to the biology of the
      tumour without the prognostic information achieved by SLNB on the nodal status to verify
      whether, in presence of a negative preoperative axillary assessment, the patients' quality of
      life can be improved by a less invasive surgical procedure.

      Endpoints

      The primary endpoint of the study is distant-disease free survival. This endpoint, a proxi of
      overall survival, will allow to have reliable results in a shorter period of time compared to
      overall survival.

      Secondary endpoints will be the cumulative incidence of distant recurrences, the cumulative
      incidence of axillary recurrences, the disease free survival (DFS) and the overall survival
      (OS). Other secondary endpoints are quality of life and evaluation of type of adjuvant
      treatment administered.

      Sample size calculation and statistical considerations

      We will consider women who will undergo SLNB as the reference group, and we will test for
      non-inferiority the group of women not undergoing any treatment in the axilla. For the
      purpose of sample size calculation, the 5-year DDFS in the reference group is assumed to be
      96.5%. Overall, 1560 women (780 per arm) will be enrolled to decide whether the group without
      treatment of the axilla is no worse than the reference group, given a margin delta of
      non-inferiority of 2.5% (maximum tolerable 5-years DDFS = 94%). Statistical power and
      one-sided type I error are set to 80% and 5%, respectively. After 3 years from the start of
      accrual an interim safety analysis will be performed.

      Standard survival analyses and survival analyses with competing events will be performed.
      Multivariable Cox regression models will be applied to adjust the risk estimates of interest
      for other variables. The Chi-square test for trend, Chi-square test and the Fisher exact test
      will be used to evaluate differences in percentages between the two treatment groups, as
      appropriate. The T-tests will be used to evaluate differences in means for continuous
      variables.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distant-disease free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of distant recurrences</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of axillary recurrences</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1560</enrollment>
  <condition>Early Stage Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: sentinel node biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sentinel node biopsy policy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No axillary staging</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arm 1: sentinel node biopsy</intervention_name>
    <description>Sentinel node biopsy policy</description>
    <arm_group_label>Arm 1: sentinel node biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast cancer &lt;2 cm, and a clinically negative axilla

          -  any age

          -  candidates to receive breast conserving surgery + radiotherapy

          -  negative preoperative assessment of the axilla (ultra-sound with or without FNAC in
             case one doubtful node is found)

          -  written informed consent must be signed and dated by the patient and the investigator
             prior to inclusion.

          -  patients must be accessible for follow-up.

        Exclusion Criteria:

          -  synchronous distant metastases

          -  previous malignancy

          -  bilateral breast cancer

          -  multicentric or multifocal breast cancer

          -  previous primary systemic therapy

          -  pregnancy or breastfeeding

          -  pre-operative diagnosis (cytology or histology) of axillary lymph node metastases

          -  pre-operative radiological evidence of multiple involved or suspicious nodes

          -  patients with psychiatric, addictive, or any disorder, which compromises ability to
             give informed consent for participation in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oreste D Gentilini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Rotmensz, Ms</last_name>
    <phone>+39 02 57489810</phone>
    <email>nicole.rotmensz@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Sangalli, Ms</last_name>
    <phone>+39 02 57489840</phone>
    <email>claudia.sangalli@ieo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Oncologico Fundacion Arturo Lopez Perez</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Badir J Chauan Manzur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprensorio Sanitario</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Graiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fulvio Ragni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico Regionale</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuseppe Murenu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Mater Domini</name>
      <address>
        <city>Castellanza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Andreoli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Anna</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvia Cattaneo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Busani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Agresti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Veronesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gennaro Limite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Rinaldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adele Sgarella, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo di Saliceto</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giorgio Macellari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Smeralda De Fazio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Cancer Center</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Anna</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mauro Porpiglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Research Institute Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francisco Ripoll Orts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsspital Bern Klinik und Poliklinik fÃ¼r Medizinische Onkologie</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Sager, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003 Aug 7;349(6):546-53.</citation>
    <PMID>12904519</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Galimberti V, Paganelli G, Maisonneuve P, Viale G, Orecchia R, Luini A, Intra M, Veronesi P, Caldarella P, Renne G, Rotmensz N, Sangalli C, De Brito Lima L, Tullii M, Zurrida S. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer. 2009 May;45(8):1381-8. doi: 10.1016/j.ejca.2008.11.041. Epub 2009 Jan 6.</citation>
    <PMID>19128957</PMID>
  </reference>
  <reference>
    <citation>Wasif N, Maggard MA, Ko CY, Giuliano AE. Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer. Arch Surg. 2010 Feb;145(2):161-6. doi: 10.1001/archsurg.2009.269.</citation>
    <PMID>20157084</PMID>
  </reference>
  <reference>
    <citation>Galimberti V, Botteri E, Chifu C, Gentilini O, Luini A, Intra M, Baratella P, Sargenti M, Zurrida S, Veronesi P, Rotmensz N, Viale G, Sonzogni A, Colleoni M, Veronesi U. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2012 Feb;131(3):819-25. doi: 10.1007/s10549-011-1486-2. Epub 2011 Apr 6.</citation>
    <PMID>21468637</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32; discussion 432-3. doi: 10.1097/SLA.0b013e3181f08f32.</citation>
    <PMID>20739842</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011 Feb 9;305(6):569-75. doi: 10.1001/jama.2011.90.</citation>
    <PMID>21304082</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002 Aug 22;347(8):567-75.</citation>
    <PMID>12192016</PMID>
  </reference>
  <reference>
    <citation>International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006 Jan 20;24(3):337-44. Epub 2005 Dec 12.</citation>
    <PMID>16344321</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, Gatti G, D'Aiuto G, Cataliotti L, Paolucci R, Piccolo P, Massaioli N, Sismondi P, Rulli A, Lo Sardo F, Recalcati A, Terribile D, Acerbi A, Rotmensz N, Maisonneuve P. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005 Mar;16(3):383-8. Epub 2005 Jan 24.</citation>
    <PMID>15668261</PMID>
  </reference>
  <reference>
    <citation>Goldhirsch A, Ingle JN, Gelber RD, Coates AS, ThÃ¼rlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009 Aug;20(8):1319-29. doi: 10.1093/annonc/mdp322. Epub 2009 Jun 17.</citation>
    <PMID>19535820</PMID>
  </reference>
  <reference>
    <citation>Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005 Mar 1;23(7):1379-89.</citation>
    <PMID>15735114</PMID>
  </reference>
  <reference>
    <citation>Montagna E, Viale G, Rotmensz N, Maisonneuve P, Galimberti V, Luini A, Intra M, Veronesi P, Mazzarol G, Pruneri G, Renne G, Torrisi R, Cardillo A, Cancello G, Goldhirsch A, Colleoni M. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Res Treat. 2009 Nov;118(2):385-94. doi: 10.1007/s10549-009-0446-6. Epub 2009 Jun 27.</citation>
    <PMID>19562480</PMID>
  </reference>
  <reference>
    <citation>Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, Giuliano AE. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009 Oct 1;27(28):4679-84. doi: 10.1200/JCO.2008.19.0686. Epub 2009 Aug 31.</citation>
    <PMID>19720928</PMID>
  </reference>
  <reference>
    <citation>Korn EL, Hunsberger S, Freidlin B, Smith MA, Abrams JS. Preliminary data release for randomized clinical trials of noninferiority: a new proposal. J Clin Oncol. 2005 Aug 20;23(24):5831-6. Epub 2005 Jul 18.</citation>
    <PMID>16027441</PMID>
  </reference>
  <reference>
    <citation>Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. Chichester, England: Wiley; 1995. 331 pp.</citation>
  </reference>
  <reference>
    <citation>Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16: 1141-1154</citation>
  </reference>
  <reference>
    <citation>Jung SH, Kang SJ, McCall LM, Blumenstein B. Sample size computation for two-sample noninferiority log-rank test. J Biopharm Stat. 2005;15(6):969-79.</citation>
    <PMID>16279355</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BC; conservative surgery; SNB; AD; axillary US imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

